Arrayed CRISPR sgRNA Libraries
Achieve reliably high knockout efficiencies across your entire CRISPR screen for any human or mouse protein-coding gene. Powered by our unique multi-guide design, our ready-to-transfect Arrayed CRISPR gRNA Libraries comprise of SpCas9 sgRNAs targeting one gene per well in a multiwell plate format. Identifying and validating your targets has never been faster and more reliable, with unparalleled quick delivery starting at 7 days and guaranteed editing efficiency.
Gene Knockout Kits
The most reliable knockout strategy, guaranteed. Knockout any human or mouse protein-coding gene with our unique multi-guide RNA strategy. Three spatially coordinated modified SpCas9 sgRNAs induce fragment deletions obtaining knockout rates greater than 80%—ships in as few as 5 days.
Knockout CD4+ T-cell Pools
Achieve unparalleled accuracy and efficiency in primary T-cell editing, bypassing the time and resources spent on optimization. Our end-to-end platform delivers ready-to-use, functionally validated T-cells, accelerating the path from discovery to clinical application.
Immortalized Express Cell Pools
Increase your speed to critical data with EditCo's Express Pools, offering an impressive 80% knockout efficiency for rapid delivery of assayable engineered cell pools. Ideal for expediting functional assays, gene target identification and validation, or pathway mapping. Receive your knockouts in less than 2 week to accelerate your research.
Knockout Immortalized Cell Lines
Fast-Track Your Research. CRISPR knockout cells streamline gene editing, providing ready-to-use cell lines and eliminating months of optimization. Choose your target, select your cell line, pools or clones, and leave the rest to us. Ensuring you meet your next research milestone with time to spare. It's time you get even more from your workhorse cell line.
Knock-in Immortalized Cell Lines
Streamline your lab work with CRISPR Knock-in Immortalized Cells. Receive precision edits for disease modeling and protein studies, bypassing the complexity of DIY CRISPR. Experience fewer repeats and rapid success with our automated process and quality reagents.
Knockout iPS Cell Lines
Human iPS cells represent the most accurate cell model, providing insights into disease progression, drug targets, and human development. EditCo's CRISPR Knockout iPS Cells redefines gene editing with industry-leading editing efficiency in iPS cells without compromising cell quality. Get reliable gene knockout for critical gene function and disease linkage studies, with the assurance of cell integrity.
Knock-in iPS Cell Lines
EditCo's advanced CRISPR knock-in edits in iPS cells unlock breakthrough potential in neuroscience and regenerative medicine. Trust in our automated, efficient process for high-quality reproducible iPS cell edits, paving the way for your groundbreaking research and therapeutic development. We've set the new gold standard for cell-based disease models.
Engineered Cell Libraries
Confidently and rapidly link genotype to phenotype. Engineered Cell Libraries enhance drug target validation by combining high editing efficiency for scalable, high-throughput CRISPR screening. Expect over 80% editing efficiency for confident selection in functional assays and drug-gene interaction studies.
Knockout CD8+ T-cell Pools
Coming soon!
Our Discovery Partnership Ecosystem
Partnerships
Partner with EditCo to harness the transformative power of genome engineering for life science R&D and drive forward human health advancements. Through our Discovery Partners Ecosystem, we offer a unified workflow from engineered cells to phenotypic data, streamlining the research process to accelerate drug discovery.
- Access comprehensive gene editing and analysis services all in one place
- Optimize efficiency and innovation in your projects.
Rapid COVID-19 Drug Target Validation with Engineered Cell Libraries
Under the leadership of Dr. Nevan Krogan, the Quantitative Biosciences Institute at the University of California, San Francisco, embarked on an urgent mission to combat COVID-19. Harnessing Synthego's Engineered Cell Libraries, the team embarked on a large-scale screening of human genes interacting with the SARS-CoV-2 virus. This approach aimed to identify and validate potential therapeutic targets quickly, bypassing the traditional years-long process. With the precision of multi-guide CRISPR designs and the efficiency of Synthego's genome engineering platforms, the project achieved unprecedented editing efficiencies in over 89% of targeted genes. This collaborative effort not only accelerated the pace of COVID-19 drug discovery but also set a new standard for rapid response in the face of infectious disease outbreaks.
- Greater than 80% editing efficiency in 89% of the targeted genes
- 400 genes screened in less than six weeks
- 40 new proviral-dependency factors crucial for SARS-CoV-2 infectivity discovered.
Large-scale variant analysis for rare disease research
TGen's Center for Rare Childhood Disorders, spearheaded by Dr. Matt Huentelman of the Neurogenomics Division, is pioneering the identification of genetic causes behind rare disorders in children through genome sequencing. Recognizing the limitations of sequencing alone, the center is embracing large-scale functional genomics to uncover what sequencing can't. EditCo’s collaboration on this groundbreaking project involved providing CRISPR edits across 60 genes within the WTC-11 iPSC line. Leveraging automated, parallel processing and advanced genome engineering techniques, EditCo’s contributions significantly expedited the research, saving valuable months and pushing the boundaries of genetic discovery in rare childhood disorders.
- Studied 12x the variants
- Delivered in ⅕ the time
- Actionable insights for better diagnostics and therapeutics
